Roy Jayeeta, Mitra Jayanta Kumar, Pal Arnab
Department of Obstetrics & Gynaecology, College of Medicine and JNM Hospital, WBUHS, Kalyani, West Bengal, India.
Australas Med J. 2013 Sep 30;6(9):483-95. doi: 10.4066/AMJ.2013.1753. eCollection 2013.
Eclampsia manifests as seizures and is unique to the pregnant state. It remains an important cause of maternal mortality especially in resource-challenged countries that lack access to prenatal care.
The aim of our study was to compare maternal and foetal outcomes in mothers with eclampsia with the administration of either magnesium sulphate or phenytoin in a resource- challenged situation.
The work was conducted from January 2012 to December 2012. A total of 80 patients were assigned alternately to two groups - one group was treated with magnesium sulphate (Group-M; n=40), and the other treated with phenytoin (Group-P; n=40) (Figure 1). The magnesium sulphate was administered according to Pritchard's regimen; phenytoin administered according to Ryan's regimen. With either regimen, anticonvulsant therapy was continued for 24 hours postpartum or 24 hours after the last convulsion, whichever was later.
Fifty-four per cent of patients regained consciousness within eight hours of treatment onset in Group-P compared to 5.3 per cent in Group-M (p=0.0001, χ(2)=19.24). Seven patients in Group-P had recurrence of convulsions as compared to none of the 40 women assigned to Group-M (p=0.032, χ(2)=4.62). The incidence of Caesarean section was greater (62.5 per cent) in Group-M compared to Group-P (25 per cent; p=0.001, χ(2)= 9.96). No statistically significant differences were found in the foetal outcomes between the two groups.
Phenytoin use may be reconsidered in selective cases in low and middle income countries (LMIC) as it has been found simpler to use, has several benefits and also curtails treatment cost. Magnesium sulphate is substantially more effective than phenytoin with regard to recurrence of convulsions. Proper training in the management of eclampsia should be given to all health care workers to ensure appropriate management of eclamptic mothers. Thus, the treatment of this disease calls for more research especially in resource-challenged settings.
子痫表现为惊厥,是妊娠状态所特有的。它仍是孕产妇死亡的一个重要原因,尤其是在缺乏产前护理的资源匮乏国家。
我们研究的目的是在资源匮乏的情况下,比较硫酸镁或苯妥英钠治疗子痫母亲的母婴结局。
该研究于2012年1月至2012年12月进行。总共80例患者交替分配到两组——一组用硫酸镁治疗(M组;n = 40),另一组用苯妥英钠治疗(P组;n = 40)(图1)。硫酸镁按照普里查德方案给药;苯妥英钠按照瑞安方案给药。无论采用哪种方案,抗惊厥治疗持续至产后24小时或最后一次惊厥后24小时,以较晚者为准。
P组54%的患者在治疗开始后8小时内恢复意识,而M组为5.3%(p = 0.0001,χ(2)=19.24)。P组有7例患者惊厥复发,而分配到M组的40名女性均无复发(p = 0.032,χ(2)=4.62)。M组剖宫产发生率(62.5%)高于P组(25%;p = 0.001,χ(2)= 9.96)。两组胎儿结局无统计学显著差异。
在低收入和中等收入国家(LMIC)的某些选择性病例中,苯妥英钠的使用可能需要重新考虑,因为它使用起来更简单,有多种益处,还能降低治疗成本。在惊厥复发方面,硫酸镁比苯妥英钠有效得多。应向所有医护人员提供子痫管理方面的适当培训,以确保子痫母亲得到恰当管理。因此,这种疾病的治疗需要更多研究,尤其是在资源匮乏的环境中。